Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MGRX vs CISS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CISS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–2 Matrix Metrics)
CISS Overall Winner
6-Pillar Tally: MGRX 2 – 4 CISS
Matrix Metrics: MGRX 2 – 5 CISS
As of Nov 20, 2026, C3is Inc. (CISS) is the stronger overall head-to-head candidate over Mangoceuticals, Inc. (MGRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MGRX carries a Unified Composite Score of 40.5/100 (SELL) at $0.12 (N/M Forward P/E, -4173.6% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin).
- Composite vs. Pillar Nuance: While MGRX currently prints a higher short-term Unified Composite Score (40.5/100 SELL vs. CISS 33.6/100 SELL), CISS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (24.6% vs. -4173.6% operating margin) and revenue trajectory (+249.0% vs. -59.1% YoY).
- Defensive Composite Rating Caution: Although CISS compares more favorably head-to-head, both MGRX (40.5/100 SELL) and CISS (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
- Technical & Structure Timing Caution: MGRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MGRX vs CISS
MGRX
Mangoceuticals, Inc. Common Stock
$0.12
-7.55% 1D
Market Cap
$3.0M
TTM Revenue
$315,227
Forward P/E
N/M
Beta / 30D Vol
1.53β · 87% Vol
Unified Composite Score
40.5
SELL
Tech 25.0
Fund 42.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
CISS
Head-to-Head Winner
C3is Inc. Common Stock
$1.23
+4.24% 1D
Market Cap
$991,199
TTM Revenue
$36.2B
Forward P/E
N/M
Beta / 30D Vol
11.91β · 1054% Vol
Unified Composite Score
33.6
SELL
Tech 5.0
Fund 29.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (MGRX 2 – 4 CISS)
1. Valuation Multiples
MGRX
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
9.8x
N/M
2. Growth & Scale
CISS
Revenue Growth (YoY)
-59.1%
+249.0%
Earnings Growth (YoY)
+0.0%
+193.3%
TTM Revenue (USD)
$315,227
$36.2B
Market Cap
$3.0M
$991,199
3. Profitability & Quality
CISS
Gross Margin
54.4%
68.1%
Operating Margin
-4173.6%
24.6%
Net Profit Margin
0.0%
27.4%
Return on Equity (ROE)
-95.1%
17.1%
4. Balance Sheet & Cash Flow
CISS
Cash Generation (TTM)
-$4.9M
$13.4B EBITDA
Cash Flow Margin
N/A
36.9% EBITDA Mgn
Net Cash / Leverage
$119,461 Net Debt (0.02x D/E)
$384.31 Book/Sh · 17.1% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MGRX
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
CISS
OpEx & R&D Intensity
N/A
43.5% of Rev ($15.8B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Health Information Services Operator
Marine Shipping Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MGRX (2) vs CISS (5)| Institutional Metric | MGRX | CISS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $3.0M | $991,199 | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -59.1% | +249.0% | CISS | |
| Operating Margin (TTM) | -4173.6% | 24.6% | CISS | |
| Net Profit Margin | 0.0% | 27.4% | CISS | |
| Return on Equity (ROE) | -95.1% | 17.1% | CISS | |
| 52-Week Range Position | 0% ($0–$1) | 20% ($0–$6) | CISS | |
| Beta / 30D Volatility | 1.53β · 87% Vol | 11.91β · 1054% Vol | MGRX | |
| Unified Institutional Score | 40.5 / 100 (SELL) | 33.6 / 100 (SELL) | MGRX | |
| Trailing 12M Revenue (USD) | $315,227 | $36.2B | Scale | |
| Gross Profit Margin (TTM) | 54.4% | 68.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 9.8x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$4.9M ($119,461 Net Debt (0.02x D/E)) | $13.4B EBITDA ($384.31 Book/Sh · 17.1% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CISS +184.64 pp
3M Horizon
CISS +14.87 pp
6M Horizon
CISS +24.71 pp
1Y Horizon
CISS +64.58 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MGRX Revenue | CISS Revenue | MGRX Op. Margin | CISS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2022 | $0M | N/A | -22279.7% | N/A | MGRX |
| FY2023 | $0M | $30M | -1260.3% | 36.3% | CISS |
| FY2024 | $0M | $40M | -1294.4% | 23.8% | CISS |
| FY2025 | $0M | $30M | -3954.3% | 3.9% | CISS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MGRX
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact MGRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CISS
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CISS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MGRX Moat Profile
Cyclical / Execution-Driven Positioning
Health Information Services Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CISS Moat Profile
Scale & Operating Efficiency Moat
Marine Shipping Operator
OpEx & R&D Reinvestment
43.5% of Rev ($15.8B)
90D Engineering Disclosures
0 Published
Investor FAQ MGRX vs CISS Key Questions & Quantitative Answers
As of Nov 20, 2026, C3is Inc. (CISS) is the stronger overall head-to-head candidate over Mangoceuticals, Inc. (MGRX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MGRX carries a Unified Composite Score of 40.5/100 (SELL) at $0.12 (N/M Forward P/E, -4173.6% operating margin), whereas CISS carries 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin). Composite vs. Pillar Nuance: While MGRX currently prints a higher short-term Unified Composite Score (40.5/100 SELL vs. CISS 33.6/100 SELL), CISS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (24.6% vs. -4173.6% operating margin) and revenue trajectory (+249.0% vs. -59.1% YoY). Defensive Composite Rating Caution: Although CISS compares more favorably head-to-head, both MGRX (40.5/100 SELL) and CISS (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MGRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CISS leads the Growth & Scale pillar: MGRX posts -59.1% YoY revenue growth and +0.0% YoY earnings growth on $315,227 TTM revenue (54.4% gross margin, -4173.6% operating margin), compared with CISS at +249.0% YoY revenue growth and +193.3% YoY earnings growth on $36.2B TTM revenue (68.1% gross margin, 24.6% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), MGRX cumulative revenue shifted N/A while CISS shifted +0.0%. In operating R&D and SG&A reinvestment, MGRX deploys N/A (0 90-day corporate R&D disclosures) versus 43.5% of Rev ($15.8B) (0 disclosures) for CISS.
MGRX screens cheaper on headline valuation multiples. MGRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.8x EV/Revenue (unreported FCF margin), whereas CISS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (36.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGRX (-95.1% ROE) versus CISS (17.1% ROE) capital efficiency.
In options market volatility and institutional positioning, MGRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 87% Vol realized risk). By comparison, CISS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.91β · 1054% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CISS vs MGRX · Reverse Pair
CISS vs AKAN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal